Compare Ishares Msci Spain ETF (EWP) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Natera Inc. Common Stock — how do they compare? Ishares Msci Spain ETF trades at $57.9 (market cap $2.31B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 24.7× Ishares Msci Spain ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Ishares Msci Spain ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Natera Inc. Common Stock for 0 Days on average.
| EWP | NTRA | |
|---|---|---|
Market Cap | $2.31B | $57.03B |
Volume | 302,484 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $425.64 |
52-Week Low | $48.95 | $179.42 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $58.34, up 0.52% on the day, with a bearish technical signal driven by moving averages. The stock faces resistance at $59 and support at $58. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights European market resilience amid ECB rate hikes and energy-driven inflation pressures.
Outlook is cautious due to bearish technicals and macroeconomic headwinds from ECB tightening. Investment opportunity hinges on Spain's equity valuation appeal, but risks include eurozone economic sentiment slippage and sustained inflation. Investors should await updated financials for fundamental assessment.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
